Clinicians develop model to calculate patient risk for NAFLD decompensation

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is associated with conditions such as obesity and metabolic syndrome, which can lead to diabetes, stroke, and heart disease. Although common, identifying people who could be at risk for NAFLD decompensation can be challenging for physicians. “We needed a way […]

Sanchez Leads NASH Drug Trial at Iowa

NASH, or nonalcoholic steatohepatitis, is a type of fatty liver disease typified by inflammation and liver cell damage and has become the most common cause of chronic liver disease worldwide. It remains a leading cause of liver transplantation in the United States and is highly prevalent in patients with obesity, insulin resistance, and dyslipidemia. But […]